Shares of Bio-Techne Corp. TECH rallied 2.14% to $52.04 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.11% ...

Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 5.3% in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical ...

Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S.

Bio-Techne Corporation TECH is set to release second-quarter fiscal 2026 results on Feb. 4, before the opening bell. The life science and diagnostic product maker posted adjusted earnings per share ...

In the latest quarter, 7 analysts provided ratings for Bio-Techne (NASDAQ:TECH), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In an ...

Life sciences company Bio-Techne (NASDAQ:TECH) in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates ...

Bio-Techne Corporation TECH recently announced new advancements in its spatial biology portfolio for the RNAscope ISH technology and the Lunaphore COMET. Research highlights the potential role of ...